Suppr超能文献

相似文献

1
A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.
J Clin Endocrinol Metab. 2017 May 1;102(5):1454-1457. doi: 10.1210/jc.2016-3903.
2
Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene.
J Atheroscler Thromb. 2013;20(5):481-93. doi: 10.5551/jat.16592. Epub 2013 Mar 7.
3
Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Endocr Pract. 2018 Aug;24(8):756-763. doi: 10.4158/EP-2018-0157.
4
Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.
J Pharmacol Exp Ther. 2016 Feb;356(2):341-53. doi: 10.1124/jpet.115.229740. Epub 2015 Nov 16.
5
Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia.
Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):158-164. doi: 10.1016/j.numecd.2017.11.003. Epub 2017 Nov 22.
7
Incidental finding of severe hypertriglyceridemia in children. Role of multiple rare variants in genes affecting plasma triglyceride.
J Clin Lipidol. 2017 Nov-Dec;11(6):1329-1337.e3. doi: 10.1016/j.jacl.2017.08.017. Epub 2017 Sep 4.
8
Successful management of acute pancreatitis due to apolipoprotein C-II deficiency in a 37-day-old infant.
Pancreatology. 2020 Jun;20(4):644-646. doi: 10.1016/j.pan.2020.03.008. Epub 2020 Mar 13.
9
Genotype-phenotype relationships in patients with type I hyperlipoproteinemia.
J Clin Lipidol. 2014 May-Jun;8(3):287-95. doi: 10.1016/j.jacl.2014.02.006. Epub 2014 Feb 17.

引用本文的文献

1
A brief clinical genetics review: stepwise diagnostic processes of a monogenic disorder-hypertriglyceridemia.
Transl Pediatr. 2024 Oct 1;13(10):1828-1848. doi: 10.21037/tp-24-131. Epub 2024 Oct 23.
2
Pancreatitis as a Main Consequence of -Related Hypertriglyceridemia: The Role of Nonsense and Frameshift Variants.
Int J Genomics. 2024 May 30;2024:6653857. doi: 10.1155/2024/6653857. eCollection 2024.
3
New approaches to triglyceride reduction: Is there any hope left?
Am J Prev Cardiol. 2024 Mar 22;18:100648. doi: 10.1016/j.ajpc.2024.100648. eCollection 2024 Jun.
4
A unified model for regulating lipoprotein lipase activity.
Trends Endocrinol Metab. 2024 Jun;35(6):490-504. doi: 10.1016/j.tem.2024.02.016. Epub 2024 Mar 23.
5
Using Synthetic ApoC-II Peptides and nAngptl4 Fragments to Measure Lipoprotein Lipase Activity in Radiometric and Fluorescent Assays.
Front Cardiovasc Med. 2022 Jul 14;9:926631. doi: 10.3389/fcvm.2022.926631. eCollection 2022.
6
Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis.
Methods Mol Biol. 2022;2419:433-459. doi: 10.1007/978-1-0716-1924-7_26.
7
Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis.
J Clin Med. 2021 Aug 13;10(16):3571. doi: 10.3390/jcm10163571.
9
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.
Pharmacol Res. 2021 Jul;169:105689. doi: 10.1016/j.phrs.2021.105689. Epub 2021 May 23.
10
Endothelial Cell Receptors in Tissue Lipid Uptake and Metabolism.
Circ Res. 2021 Feb 5;128(3):433-450. doi: 10.1161/CIRCRESAHA.120.318003. Epub 2021 Feb 4.

本文引用的文献

2
Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.
J Pharmacol Exp Ther. 2016 Feb;356(2):341-53. doi: 10.1124/jpet.115.229740. Epub 2015 Nov 16.
3
Chylomicronaemia--current diagnosis and future therapies.
Nat Rev Endocrinol. 2015 Jun;11(6):352-62. doi: 10.1038/nrendo.2015.26. Epub 2015 Mar 3.
5
LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias.
J Lipid Res. 2014 Apr;55(4):765-72. doi: 10.1194/jlr.D045963. Epub 2014 Feb 6.
8
A molecular theory of lipid-protein interactions in the plasma lipoproteins.
FEBS Lett. 1974 Jan 15;38(3):247-58. doi: 10.1016/0014-5793(74)80064-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验